Skip to main content

Now FDA-approved: FoundationOne®Liquid CDx

With the broadest gene panel of any FDA-approved blood-based test, FoundationOne Liquid CDx analyzes over 300 genes and has Medicare coverage for qualifying patients across all solid tumors.*

Directly Impacting Patient Care Today

and Shaping the Future of Patient Care Tomorrow

We are dedicated to a transformation in cancer care driven by the belief that the more we know about cancer’s molecular underpinnings, the better we can help physicians make the best treatment decisions for their patients. Through richer science, deeper insights, and stronger partnerships—we’re redefining the way cancer is treated.

Advancing Cancer Care Together

Every advancement we make today has the potential to help the next patient diagnosed tomorrow. In just ten years, we’ve made incredible progress—breakthroughs that have helped shift the treatment paradigm to directly impact patient care. Foundation Medicine, a leading decision insights company, is helping physicians connect their patients to the latest cancer treatment options—making precision medicine a reality for thousands.

For Providers

Foundation Medicine’s proven portfolio of tests and services offers the quality and commitment you need to help guide treatment strategies for all of your advanced cancer patients.

Provider Resources

For Biopharma Partners

We provide actionable insights into the oncogenomics of both rare and common cancers, fueling discovery through commercialization by using a robust database and deep experience with FDA approvals.

Biopharma Partner Resources

For Patients

Every cancer is unique. That’s why we are committed to providing specific genomic insights into your cancer to help your doctor guide a personalized care plan.

Patient Resources

More Than Numbers

Our unique knowledge base, FoundationCore®, is one of the world's largest cancer genomic databases, with more than 400,000 genomic profiles. It is designed to evaluate the genomic landscape across cancer types to better understand tumor biology, molecular biomarkers, and which treatments might work for which patients. This all helps researchers and biopharma companies develop new therapies, design better clinical trials, and advance precision medicine. 

>400k

Patients Tested

>50

Biopharma Partners

>500

Peer-reviewed Publications

Valuable Insights, Actionable Options

Our tests help to identify the genomic alterations driving a patient's cancer and match them with relevant targeted therapies, immunotherapies, and clinical trial options. We also provide decision support services, financial assistance, and technology solutions to help support all aspects of patient care.
Learn more about our products and services

Patient Story

Treating cancer means more than just dealing with the disease; it also means treating the whole person. Christine Bray, ovarian cancer survivor, shares her journey to remission after obtaining a Foundation Medicine comprehensive genomic profiling test.

We Continue to Drive for Future Breakthroughs in Patient Care

Latest CDx Test

FoundationOne®Liquid CDx is the broadest FDA-approved blood-based comprehensive genomic profiling test, providing guideline-recommended genomic results from a simple blood draw.

Learn more about FoundationOne®Liquid CDx

Additional Notes

*Medicare and Medicare Advantage members have coverage of FoundationOne Liquid CDx in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria. 

Important Safety Information

Select

FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com. 

FoundationOne Liquid CDx

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.